Gufic Biosciences Ltd

GUFIC BIOSCIENCES LIMITED

GUFIC BIOSCIENCES LIMITED has informed BSE about the appointment of a Non-Executive Independent Director.

GUFIC BIOSCIENCES LIMITED

Gufic Biosciences Limited has informed the BSE about the appointment of a Non-Executive Independent Director.

GUFIC BIOSCIENCES LIMITED

GUFIC BIOSCIENCES LIMITED has informed BSE about the appointment of a Non-Executive Independent Director.

GUFIC BIOSCIENCES LIMITED

GUFIC BIOSCIENCES LIMITED has informed BSE about the appointment of a Non-Executive Independent Director.

GUFIC BIOSCIENCES LIMITED

GUFIC BIOSCIENCES LIMITED has informed BSE about the appointment of a Non-Executive Independent Director.

GUFIC BIOSCIENCES LIMITED

GUFIC BIOSCIENCES LIMITED has informed BSE about the appointment of a Non-Executive Independent Director.

GUFIC BIOSCIENCES LIMITED

GUFIC BIOSCIENCES LIMITED has informed BSE about the appointment of a Non-Executive Independent Director.

GUFIC BIOSCIENCES LIMITED

GUFIC BIOSCIENCES LIMITED has informed BSE about the appointment of a Non-Executive Independent Director.

GUFIC BIOSCIENCES LIMITED

Gufic Biosciences Limited has informed the BSE about the appointment of a Non-Executive Independent Director.

Gufic Biosciences Ltd

Gufic Biosciences Ltd has released an investor presentation for Q2 FY2027, highlighting its business and financial updates. The company has made progress in its manufacturing platform, hospital injectable platform, women's health platform, and botulinum toxin platform. It has also expanded its international business and research and development efforts. The presentation provides a detailed overview of the company's performance and future prospects.

Gufic Biosciences Ltd

Gufic Biosciences Ltd has announced the appointment of Dr. Reeta Shah as an Additional Director (Non-Executive Independent Director) of the Company, effective December 01, 2026, subject to shareholder approval.

Gufic Biosciences Ltd

Gufic Biosciences Ltd has announced its unaudited financial results for the quarter and half year ended September 30, 2026, showing a total income of ₹55,080.17 and a net profit of ₹4,594.91. The company's earnings per share (EPS) for the half year is ₹4.58.

Gufic Biosciences Ltd

Gufic Biosciences Ltd announced unaudited financial results for the quarter and half year ended September 30, 2026, with a net profit of ₹2,348.86 lakhs from continuing operations. The company also appointed Dr. Reeta Shah as an additional director.

Gufic Biosciences Ltd

Gufic Biosciences Ltd has received an order from the Income Tax Appellate Tribunal (ITAT) regarding the assessment under Section 143(3) read with Section 144B of the Income Tax Act, 1961 for the Assessment Year 2023-24. The order has allowed both the Department's appeal and the Company's cross-objection for statistical purposes, set aside the findings of the CIT(A), and restored the matters to the file of the Assessing Officer for fresh consideration.

Gufic Biosciences Ltd

Gufic Biosciences Ltd has informed that the USFDA conducted a pre-approval inspection at its manufacturing facility in Indore, Madhya Pradesh from October 15-23, 2026, and received 3 observations in Form FDA 483. The company will address these observations within the stipulated timeframe.

Gufic Biosciences Ltd

Gufic Biosciences Ltd has announced a newspaper advertisement regarding a Special Window for Re-lodgement of Transfer and Dematerialization of Physical Shares, as per SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026.

Gufic Biosciences Ltd

Gufic Biosciences Ltd has submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026, confirming the dematerialisation of securities and listing on stock exchanges.

Gufic Biosciences Ltd

Gufic Biosciences Ltd has received an appellate order from the Commissioner of Income Tax (Appeal) allowing its appeal against an income tax demand of Rs. 4,33,36,680 for the Assessment Year 2024-25.

Gufic Biosciences Ltd

Gufic Biosciences Ltd has announced the closure of its trading window for all designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ended September 30, 2026.

Gufic Biosciences Ltd

Gufic Biosciences Ltd has received an ESG rating of CRISIL ESG 62 (Category: Strong) from Crisil for FY 2025-26, based on publicly available information.